Results 151 to 160 of about 32,890 (266)

Recurrent Pneumothorax in a Pediatric Patient with Crohn’s Disease Receiving Ustekinumab Treatment: Case Report

Case Reports in Gastroenterology
Introduction: We present the case of a patient with Crohn’s disease who experienced recurrent pneumothorax after starting treatment with ustekinumab.
Marta Freixas Bermejo, Luis Riera Soler, Laura García Martínez, Oscar Segarra Cantón   +3 more
doaj   +1 more source

Adalimumab‐responsive Monogenic Inflammatory Bowel Disease With Pseudopolyposis Characteristic of TGFBR2 Variant in Loeys‐Dietz Syndrome

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Loeys‐Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder caused by pathogenic variants in TGFBR1 or TGFBR2. It is characterized by vascular fragility, skeletal abnormalities, and predisposition to allergic and inflammatory conditions, including monogenic inflammatory bowel disease (IBD).
Tomomitsu Sado, Satoshi Ukai, Shingo Kurasawa, Yosuke Kono, Norio Hasuda, Mai Iwaya, Takaya Nakane, Tomomi Yamaguchi, Tomoki Kosho, Yoshiko Nakayama   +9 more
wiley   +1 more source

Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial

Acta Dermato-Venereologica
Mild psoriasis may be burdensome; if symptoms are inadequately controlled, switching therapy may be warranted. In the Phase 3 NAVIGATE trial, patients with moderate-to-severe plaque psoriasis received ustekinumab for 16 weeks.
Enzo Errichetti, Peter Wolf, Saakshi Khattri, Patricia Gorecki, Megan Miller, Jingzhi Jiang, Chenglong Han, Brian Kirby   +7 more
doaj   +1 more source

Utility of Hybrid Endoscopy Combining Small‐Bowel Capsule Endoscopy and Conventional Ileocolonoscopy in Crohn's Disease

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Objectives To evaluate the safety and utility of hybrid endoscopy for whole‐bowel assessment in Crohn's disease (CD) and its role in treatment decision‐making. Methods This single‐center retrospective study included 125 patients with CD in clinical remission (Crohn's Disease Activity Index ≤150) who underwent hybrid endoscopy between February ...
Takahiro Ito, Kohei Matsunaga, Yuya Ohno, Muchir Shi, Atsuo Maemoto   +4 more
wiley   +1 more source

Treatment Resistant Atopic Dermatitis: Challenges and Solutions [Corrigendum]

Clinical, Cosmetic and Investigational Dermatology, 2019
Johnson BB, Franco AI, Beck LA, Prezzano JC. Clin Cosmet Investig Dermatol. 2019; 12:181–192.On page 189, Ustekinumab section, “Ustekinumab is a human monoclonal antibody that binds to the shared p40 protein subunit of human IL-12 and IL-23 ...
Johnson BB, Franco AI, Beck LA, Prezzano JC   +3 more
doaj  

Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study

Therapeutic Advances in Gastroenterology
Background: The risk of serious infection and active tuberculosis in patients with inflammatory bowel disease (IBD) has not been concurrently evaluated based on the use of anti-tumor necrosis factor (TNF)-α agents versus non-anti-TNF biologics ...
Min Jee Kim, Ye-Jee Kim, Daehyun Jeong, Seonok Kim, Seokchan Hong, Sang Hyoung Park, Kyung-Wook Jo   +6 more
doaj   +1 more source

Efficacy and Safety of Second‐Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID

United European Gastroenterology Journal, Volume 14, Issue 3, April 2026.
ABSTRACT Background and Aims Vedolizumab has become the preferred first‐line advanced therapy in ulcerative colitis (UC). However, the optimal second‐line treatment following vedolizumab failure remains unclear. We aimed to evaluate the effectiveness and safety of second‐line therapies after first‐line vedolizumab.
Louis Calméjane, Catherine Reenaers, Claire Gay, Aurélien Amiot, Alexandre Nuzzo, Lucine Vuitton, Calina Atanasiu, Carmen Stefanescu, Romain Altwegg, Lucas Guillo, Mélanie Serrero, Guillaume Bouguen, Maria Nachury, Guillaume Le Cosquer, Xavier Roblin, Vered Abitbol, Nassim Hammoudi, Marion Simon, Mathurin Fumery, Guillaume Savoye, Alban Benezech, Maryan Cavicchi, Maeva Charkaoui, Anthony Buisson, Bénédicte Caron, Benoît Coffin, Sophie Geyl, Félix Goutorbe, Marianne Hupé, Mathias Vidon, David Laharie, Julien Kirchgesner, Mathieu Uzzan, on behalf ofthe GETAID‐AFTER‐VEDO Study Group   +33 more
wiley   +1 more source

Assessing Functional Similarity of Biosimilar ABP 654 and Ustekinumab in Samples from Patients with Crohn’s Disease

Journal of Inflammation Research
Ian N Foltz,1 Kevin Gaida,2 Helen Y Wong,1 Michael Ng,1 Marijana Busch,1 Jennifer L Liu3 1Amgen Research, Department of Therapeutic Discovery, Amgen Inc., Burnaby, BC, V5A1V7, Canada; 2Research and Development, Amgen Inc., Thousand Oaks, CA, 91320, USA ...
Foltz IN, Gaida K, Wong HY, Ng M, Busch M, Liu JL   +5 more
doaj  

Intestinal Ultrasound Transmural Healing Was Associated With Improved Long‐Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 992-999, April 2026.
This a prospective study showing the benefit of intestinal ultrasound transmural healing on long term outcome among patient with partial and complete endoscopic healing in Crohn's disease. ABSTRACT Background STRIDE II guidelines recognise endoscopic healing as a main therapeutic target in Crohn's disease (CD).
Clara Yzet, Amélie Plancke, Franck Brazier, Lucien Grados, Elise Derval, Louise Ghilardi, Momar Diouf, Adrien Ollier, Mathurin Fumery   +8 more
wiley   +1 more source

Two‐Stage Surgical Management of Anogenital Hidradenitis Suppurativa in Patients on Biologic Therapy: A Retrospective Case Series

International Wound Journal, Volume 23, Issue 4, April 2026.
ABSTRACT Hidradenitis suppurativa is a chronic inflammatory skin disorder causing painful nodules, abscesses and scarring, with the anogenital region presenting particular functional and reconstructive challenges. Although biologic therapy is commonly used in moderate to severe disease, its limitations highlight the role of surgery in advanced cases ...
Nino Fuchs, Lucija Pavljak, Dinko Hauptman, Marko Mance   +3 more
wiley   +1 more source